ALGNAlign Technology

Health care · Medical Devices · Nasdaq

Employees: 20,290
Headquarters: Tempe, AZ
CEO: Joseph Hogan
Next results: around Feb 3, 2027

RevenueFY2016–25 $4.0B+0.9% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $410.4M−2.6% FY2024: $421.4M 10-K FY2025 · XBRL Free cash flowFY2016–25 $490.8M−21.2% FY2024: $622.7M 10-K FY2025 · XBRL Operating marginFY2016–25 13.5%−1.7 pts 23.1% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 27, 2026 against Feb 28, 2025

Area	What changed	Source
Risk factors	18 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Accounting checks	11 other checks clear	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	4 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 27, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-28. Quoted as filed.

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our financial condition or results of operations.
10-K, Item 1A

All 18 new paragraphs →

Accounting checks

latest 10-K

11 of 11 clear 0 worth a look. Checks, not verdicts.

✓
Receivables +10.7% vs revenue +0.9% (+9.8 pts)
✓
Cash from operations $593.2M vs net income $410.4M (FY ending 2025-12-31)
✓
Inventory -11.0% vs revenue +0.9% (-11.9 pts)
✓
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
The same matters as last year: Revenue Recognition - Determination of Standalone Selling Price of Distinct Performance Obligations in Clear Aligner Contracts
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nov 6, 20268-K Material agreement signed, New debt or obligation 8-K items 1.01, 2.03
Nov 4, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
Oct 28, 2026Officer CEO change Davis’s appointment as CEO-elect and her anticipated appointment as President and CEO, the Company and Ms.
Oct 28, 20268-K Quarterly results 8-K item 2.02

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on ALGN in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/ALGN/export.csv") into a cell.